Eli Lilly's Triple-Hormone Obesity Drug Retatrutide Opens Early Access Before FDA Approval

Eli Lilly is expanding pre-approval access to its experimental weight loss drug retatrutide, a novel triple-hormone therapy that achieved 73 to 85 pounds of weight loss over two years in clinical trials. The move comes as the company plans to file for FDA approval in the first quarter of 2027, offering a potential lifeline for severely obese patients who cannot enroll in ongoing trials.

Vital Signs

• 22.6% average weight loss in an 80-week trial of adults with...